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Introduction
Staphylococcus aureus is one of the most common 
opportunistic pathogens carried by approximately 
30–50% of humans and continues to be a leading 
cause of infection-related deaths, ranging from 6–40% 
around the globe (Frank et al. 2010; Islam et al. 2020). 
Although the axilla, throat, and perineum are essen-
tial reservoirs, the anterior nares are the primary niche 
for S. aureus and serve as a reservoir for the pathogen’s 
spread (Lowy 1998). S. aureus nasal colonization causes 
a range of mild infections to life-threatening conditions, 
including fatal endocarditis, pneumonia, bacteremia, or 
chronic osteomyelitis. Additionally, it is a risk factor for 
life-threatening surgical site infections and infections in 
dialysis (Mitchell and Howden 2005). So far, antibiotic 
therapy has been the best option for treating S. aureus. 
However, S. aureus infections have become a  serious 
global challenge because of resistance to a wide range 
of clinically significant antibiotics and a limited num-
ber of new antibiotics. Previous studies showed that 
the rate of discovery of new antibiotics is slowing, 
while the occurrence of antibiotic-resistant infections 
is increasing sharply, therefore, the rate of antibiotic 
withdrawal from the healthcare system is higher than 
that of approvals (Kinch et al. 2014). In addition, the 
current antibiotic regimen reduces and changes the 
skin’s microbial composition and supports pathogen 
overgrowth (Chambers and Deleo 2009; Song et al. 
2018), highlighting the need to develop new drugs that 
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A b s t r a c t
Staphylococcus aureus is currently a significant multidrug-resistant bacterium, causing severe healthcare-associated and community-
acquired infections worldwide. The current antibiotic regimen against this pathogen is becoming ineffective due to resistance, in addition, 
they disrupt the normal microbiota. It highlights the urgent need for a pathogen-specific drug with high antibacterial efficacy against 
S. aureus. α-Viniferin, a bioactive phytochemical compound, has been reported to have excellent anti-Staphylococcus efficacy as a topical 
agent. However, so far, there were no clinical trials that have been conducted to elucidate its efficacy. The present study aimed to investigate 
the antibacterial efficacy of α-viniferin against S. aureus in a ten-day clinical trial. Based on the results, α-viniferin showed 50% minimum 
inhibitory concentrations (MIC50 values) of 7.8 µg/ml in culture broth medium. α-Viniferin was administered in the nares three times a day 
for ten days using a sterile cotton swab stick. Nasal swab specimens were collected before (0 days) and after finishing the trial (10th day), 
and then analyzed. In the culture and RT-PCR-based analysis, S. ureus was reduced significantly: 0.01. In addition, 16S ribosomal RNA-
based amplicon sequencing analysis showed that S. aureus reduced from 51.03% to 23.99% at the genus level. RNA-seq analysis was also 
done to gain insights into molecular mechanisms of α-viniferin against S. aureus, which revealed that some gene groups were reduced in 
5-fold FC cutoff at two times MIC conditions. The study results demonstrate α-viniferin as a potential S. aureus-specific drug candidate. 
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not only serve as effective alternatives to the current 
drug regimen but also preserve skin microbiota. 
Natural products and secondary metabolites pro-
duced by living systems, mostly plants, have a  wide 
range of pharmacological properties, including antimi-
crobial and anti-inflammatory ones, and a high potential 
for treating human diseases, such as coronary heart dis-
eases, cancer, diabetes, and infectious diseases (Chabán 
et al. 2019). According to the World Health Organiza-
tion, 65–80% of the world’s population depends on 
traditional medicine to treat many diseases (Chew 
et al. 2011). α-Viniferin is a phytochemical compound 
extracted from Carex humilis, a medicinal plant that 
grows in eastern Asian countries, such as Japan, China, 
and Korea (Seo et al. 2017). It was also identified from 
Iris clarkei, Caragana Sinica, and Caragana chamlagu 
(Chung et al. 2003). α-Viniferin isolated and identified 
as a stilbene oligomer has various biological activities, 
including antioxidant, anti-tumor, anti-cancer, and anti-
arthritis. It has also been reported to inhibit cyclooxy-
genase, acetylcholinesterase, and prostaglandin H-2 
synthase (Sim et al. 2014; Seo et al. 2017). Additionally, 
α-viniferin shows antibacterial activity against drug-
susceptible and drug-resistant strains of Mycobacterium 
tuberculosis and excellent anti-Staphy lococcus activity 
against three Staphylococcus species, including methi-
cillin-susceptible S. aureus (MSSA), methicillin-resistant 
S. aureus (MRSA), and methicillin-resistant Staphylo-
coccus epidermidis (MRSE) (Seo et al. 2017). Previous 
studies using animal models have demonstrated that 
α-viniferin improves general health in mammals and is 
rapidly absorbed in the blood stream (Baur et al. 2006; 
Fan et al. 2020). Although α-viniferin is assumed to be 
a potential S. aureus-specific drug, there were no clini-
cal studies on its effects on S. aureus to the best of our 
knowledge. In this study, we investigated α-viniferin 
clinical efficacy in eradicating S. aureus from the nasal 
carriage. Additionally, we looked over the effectiveness 
of α-viniferin against nasal MRSA.
Experimental
Materials and Methods
α-Viniferin and its antimicrobial inhibition. We 
purchased the α-viniferin, pale brown powder (Cat No.: 
CFN97068) from Chem Faces (Wuhan, Hubei, China) 
and confirmed its specific toxicity against 20 bacterial 
strains obtained from the National Culture Collec-
tion for Pathogens (NCCP) (Chungbuk, Korea). The 
minimal inhibitory concentration (MIC) of α-viniferin 
against each bacterial strain was determined using 
cation-adjusted Mueller-Hinton broth according to the 
Clinical and Laboratory Standards Institute (CLSI). 
Each well of a 96-well plate was inoculated with 200 µl 
of the inoculum suspension (1 × 105 to 1 × 106 CFU/ml) 
and the plates were incubated for 24 h. The MIC val-
ues were determined as the lowest drug concentrations 
that showed complete inhibition of visible growth. 
The bacterial strains were as follows: Escherichia coli 
NCCP 14762, Proteus vulgaris NCCP 14765, Shigella 
boydii NCCP  14745, Shigella flexneri NCCP  14744, 
Shigella dysenteriae NCCP 14746, Staphylococcus aureus 
NCCP 14780, Staphylococcus epidermidis NCCP 14768, 
Sta phylo coccus aureus MRSA NCCP 14769, Coryne- 
bacterium diphtheriae NCCP 10353, Salmonella ente- 
ritidis NCCP 14771, Acinetobacter baumannii NCCP 
14782, Streptococcus sangunis NCCP 14775, Streptococ-
cus pyo ge nes NCCP 14783, Streptococcus pneumoniae 
NCCP 14774, Serratia marcescens NCCP 14770, Citro-
bacter freundii NCCP  14766, Enterobacter aerogenes 
NCCP 14761, Proteus mirabilis NCCP  14763, Kleb- 
siella pneu moniae NCCP  14764, and Escherichia coli 
O157 NCCP 14541.
Study design and subjects. Our study enrolled 
20 Korean adult females aged between 20 and 60 years 
following inclusion and exclusion criteria. The inclu-
sion criteria comprised health and physical fitness, age 
> 18 years, and the willingness to avoid topical agent 
applied to the nares during the entire trial. The char-
acteristics of the subjects are shown in Table SI. The 
Institutional Review Board approved this study of the 
Korea Dermatology Research Institute (IRB Number: 
KDRI-IRB-20231, Study Code: KDRI-2020-231). We 
obtained written informed consent from all participants 
before conducting the study. The study was carried out 
according to the 1964 declaration of Helsinki. 
Clinical experiment. Following the randomiza-
tion sequence, we sequentially numbered containers 
with the study drug, α-viniferin, and provided it to the 
numerical order participants. Nare’s specimens were 
collected on day 0 and at day ten by a professional. Dur-
ing the trial, each participant’s skin moisture content 
was measured on days 0, 4, and 8 using a corneometer 
CM 825 (Courage and Khazaka, Germany). Each time, 
the corneometer measurement was done five times at 
constant temperature and humidity (20–24°C, 40–60% 
RH), at the same site, in the same way, and the aver-
age value was recorded as an immediate value. The 
recorded value was then analyzed to observe our study 
drug’s moisturizing power because moisture content 
plays a key role in maintaining an intact skin barrier 
(Mojumdar et al. 2017). During and immediately after 
the test, a dermatologist examined the skin for irritation 
or allergic symptoms. 
Skin irritation test. Before the clinical trials, 
a skin irritation test for three concentrations of α-vini- 
ferin (10 µg/ml, 100 µg/ml, 1,000 µg/ml) was done on 
32 Korean adult females in a different place to rule 
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out the possibility of skin irritation of the test drug. 
The characteristics of the participants are shown in 
Table  SII. The drug solution was loaded into a clear 
patch chamber, and then the patches were applied onto 
the participants’ backs. All participants were advised 
to avoid water, heavy exercise, and scratching. The 
patch chambers were removed after 48 hours. After 
thirty minutes of patch removal (total 48 hours test), 
the reaction site was observed and observed again 
after 24 hours (total 72  hours of the test). The reac-
tions were graded according to the recommendation 
of the International Contact Dermatitis Research 
Group (ICDRG), and Frosch and Kligman (Frosch and 
Kligman 1979; Lachapelle and Maibach 2020). This 
study was approved by the Institutional Review Board of 
the COREDERM Skin Research Center (IRB Number: 
CDIRB-QR-20-025, Study Code: CDS-2000-005-14). 
We obtained written informed consent from all partici-
pants before conducting this study. 
Preparation and application of α-viniferin. We 
prepared α-viniferin suspension by mixing the powder 
with sterile distilled water at 100 mg/l. A sterile cot-
ton swab (BD Difco, USA) was used to treat the nares; 
the swab was moistened with the drug suspension and 
then gently rubbed the anterior nares while rotating it 
for 15 seconds. The drug was applied three times daily 
for ten days in right and left nares. The participants 
themselves made the application of the drug solution.
Sample collection. An expert did the collection of 
nasal specimens at day zero (0) and the end of the trial 
(at day 10), by swabbing the anterior nares with sterile 
foam-tipped swabs moistened with a mixed solution 
of 0.15 M NaCl and 0.1% Tween 20 solution (Sigma-
Aldrich, France) (You et al. 2019). Each region was 
swabbed for 15 seconds while rotating the swab and 
exerting gentle pressure. Each swab was then placed 
into the swab container without touching any objects 
and transported to the laboratory in a dry-ice bag con-
tainer within two hours of collection. 
Culture of microorganisms. Upon receiving the lab 
samples, we added 2 ml 0.15 M NaCl solution into the 
swab container, vortexed it enough, and transferred it 
into a fresh microcentrifuge tube. After doing a 10-fold 
serial dilution four times (10–1 to 10–4) in 0.15 M NaCl 
solution, we placed a 10-µl sample from each of the dilu-
tion-tube in duplicate onto the nutrient agar, a staphy-
lococcus agar medium (BD Difco, USA), and a second 
staphylococcus agar medium containing methicillin 
antibiotic (50 µg/ml) for the culture-based quantifica-
tion of nasal microbiota, S. aureus, and MRSA, respec-
tively, using a spread plate method. After 48 hours of 
incubation at 37°C, plates were inspected for the growth 
of colonies with morphology characteristic of S. aureus. 
We distinguished S. aureus from other Staphylococcus 
species by its round and golden-yellow colonies. For 
each dilution, the average of the two duplicate plates 
was calculated. When two successive dilutions yielded 
30 to 300 colonies, the average count of both dilutions 
was calculated. We stored the rest of the samples at 
–80°C for further molecular analysis. 
DNA extraction. We extracted DNA for real-time 
quantitative PCR (qRT-PCR) and next-generation 
sequencing (NGS)-based 16S rRNA profiling by thaw-
ing samples and transferring them to Lysing Matrix B 
tubes aseptically (MP, Biomedicals, USA), followed 
by mechanical lysis through bead beading. After cen-
trifuging enough, we collected supernatant without 
any visible particles. Next, we checked the quality of 
extracted DNA by agarose gel electrophoresis and visu-
alized it using ethidium bromide (Bio-Rad, ChemiDoc, 
USA). We also quantified the isolated DNA by a Qubit 
Fluorometer using a dsDNA HS Assay kit (Invitrogen, 
USA). We used a 0.15 M NaCl solution as a negative 
control to ensure no DNA contamination occurred dur-
ing the whole process (Rainer et al. 2020). 
qRT-PCR. We did qRT-PCR (C1000 Thermal Cycler) 
to test for the presence and quantification of S. aureus 
and MRSA in the nasal swab samples separately, target-
ing organism-specific genes is a significant correlation 
between PCR cycle threshold (Ct) value and bacterial 
load (Dionne et al. 2013; Davies et al. 2018). We used 
the following primers in this study: SA1 (5’-AATCT- 
TTGTCGGTACACGATATTCTTCACG-3’) and SA2 
(5’-CGTAATGAGAT T TCAGTAGATAATACA 
ACA-3’) specific for S. aureus (Pereira et al. 2010); and 
MRS1 (5’-TAGAAATGACTGAAC GTCCG-3’) and 
MRS2 (5’-TTGCGATCAATGTTACC GTAG-3’) 
specific for MRSA (Del Vecchio et al. 1995). We also 
used 16S rRNA universal primers to quantify resident 
nasal microbiota. We did the assay in a final volume 
of 20 µl consisting of a 5-µl extracted template DNA 
and 15 µl reaction mixtures: 4 µl nuclease-free water, 
10 µl iQ SYBR Green Supermix (Bio-Rad Laboratories, 
USA), and 0.5 µl each of the forward and reverse primer 
(10 pmol/µl). We did amplification as follows: an ini-
tial DNA denaturation and enzyme activation at 95°C 
for 3 min, followed by 49 cycles of a 10-s denaturation 
step at 95°C, a 10-s annealing step at 55°C, and a 30-s 
extension step at 72°C. 
Absolute quantification. To make a qRT-PCR 
standard curve (threshold cycle versus the number of 
CFU/ml curve), we cultivated an S. aureus stock culture 
(0.1% inoculation) in Mueller-Hinton broth (BD Difco, 
USA) for 6–8 hours at 37°C using a shaker incubator 
(BioFree, Korea). We then checked the optical density 
(OD at 600 nm) using a spectrophotometer (DR 1900, 
Hach, USA); it was 0.8 to 1.0. Next, we centrifuged the 
broth culture to get the bacterial pellet at 1,811.16 × g for 
10 mins employing a Hanil combi R515 (Hanil Scien tific 
Inc., Korea) serially diluted the pellet 10-fold eight times 
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using sterile distilled water. After that, we extracted 
DNA through mechanical lysis as described in the DNA 
Extraction section, amplified it by qRT-PCR, and used 
the data to create the standard curve in which each tar-
get CFU is plotted against the resulting Ct value. 
16S rRNA-based amplicon sequencing. Following 
the DNA extraction, we amplified the V4 hyper-variable 
region of the 16S ribosomal RNA gene. We used the V4 
region-specific primers with a locus-specific overhang 
sequence: 515F-5’ – TCGTCGGCAGCGTCAGATGT-
GTATAAGAGACAG- GTGCCAGCMGCCGCGGTAA 
and 806R – 5’-GTCTCGTGGGCTCGGAGATGTG-
TATAAGAGACAG-GGACTACHVGGGTWTCTAAT 
(overhang sequence-locus specific-sequence). We atta-
ched indexes and Illumina sequencing adapters through 
index PCR using a Nextera XT Index kit v2 (Illumina, 
USA). We used Agencourt AMPure XP (Beckman 
Coulter, USA) beads after every PCR step to purify the 
PCR products and quantified them using the Qubit 
dsDNA HS Assay kit (Invitrogen, USA). We then nor-
malized the samples, pooled, mixed them with PhiX 
Control v3 (Illumina), and sequenced them using Illu-
mina iSeq 100 platform (Illumina). Finally, we analyzed 
the sequence data using Ezcloud software that exhibits 
the entire microbial profile within the sample tested.
Gene expression profiling. Drug treatment, RNA 
extraction, and analysis. To understand how α-viniferin 
downregulate S. aureus gene expression, we treated 
an S. aureus broth culture with α-viniferin, extracted 
RNA, and sent it for the RNA sequencing. We culti-
vated S. aureus culture and measured optical density as 
described in the absolute quantification section. Then, 
we distributed the broth culture into three tubes; each 
tube contained 30 ml of broth. Afterward, we added 
a specific volume of α-viniferin stock solution to the 
tubes separately to make the drug concentration 1 × 
the MIC value (10 µg/ml) and 2 × the MIC value (20 µg/
ml). We also used drug-free 0.15 M NaCl solution in 
one of the tubes as a negative control. We then incu-
bated the drug-treated and drug-free culture at 37°C 
for 6–8 hours on a shaker incubator. After the incuba-
tion, we extracted total RNA from the broth cultures of 
S. aureus using the RNA Protect Bacterial Reagent and 
RNeasy Mini kit (QIAGEN, Germany), according to the 
manufacturer’s instructions (RNeasy Mini Handbook). 
We also used an RNase-free DNase set (QIAGEN) for 
the degradation of the existing DNA. We assessed the 
quality of the isolated total RNA through 2% agarose 
gel electrophoresis since high-quality RNA is a prereq-
uisite for ensuring all expressed genes’ representation. 
We sent RNA samples for RNA sequencing, which has 
become a standard tool for analyzing gene expression in 
bacterial infections (Saliba et al. 2017). We did an RNA 
sequencing assay using a commercial RNA sequencing 
service (Ebiogen, Seoul, Korea). 
Library preparation, sequencing, and data anal-
ysis. We used a QuantSeq 3’mRNA-Seq Library Prep 
Kit (Lexogen, Inc., Austria) to construct an RNA 
library following the manufacturer’s instructions. In 
brief, we hybridized 500 ng of the total RNA with an 
oligo-dT primer containing an Illumina-compatible 
sequence at the 5’ end, followed by reverse transcrip-
tion. We initiated the second-strand synthesis using 
a random primer containing an Illumina-compatible 
linker sequence at its 5’ end after the degradation of 
the RNA template. We used magnetic beads to remove 
all the reaction components and purify the double-
stranded library. We then amplified the library to add 
the entire adapter sequences essential for cluster gen-
eration. Finally, we purified the complete library from 
PCR components, did a high throughput sequencing 
as single-end 75 sequencing using NextSeq 500 (Illu-
mina). After the sequencing, we used Bowtie2 to align 
the QuantSeq 3’mRNA-Seq reads. We created Bowtie2 
indices from either a representative transcript sequence 
or a  genome assembly sequence for aligning with 
genome and transcriptome. We used alignment files 
for assembling transcripts, estimating their abundances, 
and detecting different expressions of genes. We used 
Bedtool coverage to find the differentially expressed 
genes based on counts from unique and multiple align-
ments. We processed the RT (Read Count) data based 
on Quantile normalization using EdgeR within R using 
Bioconductor. We based gene classification on searches 
done in the DAVID (http://david.abcc.ncifcrf.gov/) and 
Medline databases (http://www.ncbi.nlm.nih.gov/). 
Statistical analysis. We analyzed the corneometer 
value, CFU, and qRT-PCR data using Prism 7.0 (Graph-
Pad Software, Inc., La Jolla, USA). We used a two-tailed 
Student’s t-test to evaluate the statistical significance of 
the results of three independent experiments done in 
triplicate. In the graph, data are represented as mean 
± standard deviation (SD). Means were considered to be 
significant at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001). We analyzed NGS-based 16S rRNA 
sequencing data using Ezcloud software. We also used 
the hypergeometric distribution to analyze the RNA 
sequencing data. 
Results
Antimicrobial inhibition. Antibacterial inhibition 
of α-viniferin was tested against 20 bacterial isolates. 
The antibacterial activities of α-viniferin and two ref-
erences antibiotics VAN and MET, expressed as MICs, 
are shown in Fig. 1, where MICs values were expressed 
up to 100 µg/ml. However, in this study, α-viniferin 
showed excellent anti-staphylococcus efficacy with the 
MIC value of 7.8 µg/ml against three Staphylococcus 
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species including methicillin-susceptible S. aureus 
(MSSA), methicillin-resistant S. aureus (MRSA), and 
methicillin-resistant S. epidermidis (MRSE) with no 
toxicity to other bacterial strains (Fig. 1A). The refer-
ence drug VAN was also active against three Staphylo-
coccus species, but it also showed toxicity against other 
bacterial strains (Fig. 1B), and MET was also tested as 
a second reference drug (Fig. 1C). These results indicate 
α-viniferin as a potential antibacterial agent with spe-
cific toxicity against Staphylococcus group. 
Clinical experiment. We performed a 10-day clini-
cal trial to investigate the antimicrobial efficiency of 
α-viniferin, in which 20 healthy Korean adult females 
participated. The drug was applied in the right and 
left anterior nares three times daily. We collected the 
nasal swab samples before (day 0) and after conducting 
Fig. 1. Antimicrobial inhibition. Antibacterial activities, expressed as MICs, of α-viniferin (A), Vancomycin (B) and Methicillin (C) 
against 20 bacterial isolates. Bacterial suspensions (1 × 105 to 1 × 106 CFU/ml) were incubated with varying concentrations of α-viniferin, 
Vancomycin, Methicillin in Mueller Hinton Broth in a 96 well plate for 24 h at 37°C. In vitro MICs were determined by the broth dilu-
tion procedures described by the Clinical and Laboratory Standards Institute (CLSI).
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the clinical trial (day 10), and we analyzed them 
through culture-based and molecular-based tech-
niques (Fig. 2A). We also measured each participant’s 
skin surface’s hydration level using a corneometer at 
day 0, fourth, and eighth, respectively, and then the 
corneometer value, A.U, was analyzed. We observed 
that skin moisture content increased to a statistically 
significant level (p < 0.001) at day 4 (21.11%) and at 
day 8 (41.10%), compared to day 0, demonstrating the 
moisturizing power of α-viniferin (Fig. 2B). 
Skin irritation test. A skin irritation test of α-vini-
ferin was done in 32 healthy females in different loca-
tions before performing the clinical trial; with all par-
ticipants, after the patch was attached for 48 hours, 
α-viniferin did not show skin irritation or allergic reac-
tions at 30 mins and 24 hours after patch removal. The 
mean values with three different α-viniferin concentra-
tions in both cases were 0.00 and were classified as hav-
ing a low range (0.00–0.87) irritation potential accord-
ing to the classification criteria (Table I). These results 
ensure the safety profile of α-viniferin as a topical agent.
Culture-based quantification. To enumerate the 
culturable bacteria, S. aureus, and MRSA in the drug-
free and α-viniferin-treated samples, we collected nasal 
1. α-viniferin 10 0 –b – – – – 0.00 – – – – – 0.00 0.00
2. α-viniferin 100 0 – – – – – 0.00 – – – – – 0.00 0.00
3. α-viniferin 1,000 0 – – – – – 0.00 – – – – – 0.00 0.00
4. Negative control 0 – – – – – 0.00 – – – – – 0.00 0.00
Table I
Skin irritation test result.
a – Mean: (mean value of skin reaction at 48 hrs. + mean value of skin reaction at 72 hrs.)/2. (Mean score: 0.00 ~ 0.87, low; 0.88 ~ 2.42, mild; 
2.43 ~ 3.44, moderate; 3.45 ≤, severe)
b – “–“: No reaction. (Reaction score: 0, –, no reaction; 0.5, ±, Barely perceptible erythema, Doubtful or questionable reaction; 1, +, Slight erythema, 






30 min. after patch removal (48 hrs.) 24 hrs. after patch removal (72 hrs.)
Meana
4+mean mean3+2+1+0.5+0.5+ 4+3+2+1+
Fig. 2. Clinical experiment of α-viniferin. General overview of 
clinical experiment. α-Viniferin was treated three times daily 
both in the left and right nares using a sterile cotton swab stick 
for 10 days. Nasal specimens were collected at 0th day (drug-free) 
and 10th day (α-viniferin treated) and analyzed (A). Skin Mois-
ture Content Measurement. Skin moisture content was also mea-
sured during the α-viniferin treatment at day 0, 4, and 8 respec-
tively, using coreometer. After a 4-day and 8-day treatment, the 
skin moisture content of the area was increased dramatically 
(p < 0.001) to 21.11% and 41.10% respectively, compared to at 
day 0 (B). The experiments were performed in triplicate, and the 
data are represented as mean values and standard deviations. *Sta-
tistical significance vs. drug-free control using one-way ANOVA 
(*p < 0.05, **p < 0.01, ***p < 0.001).
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specimens on day 0 and tenth. We assayed them on 
the nutrient agar, staphylococcus agar medium, and 
a  staphylococcus agar medium containing methicil-
lin (50 µg/ml) through spread-plate techniques. After 
incubation, we analyzed the resulting CFU data, which 
revealed that the samples’ bacterial content remained 
almost constant throughout the clinical trial period. The 
average number of commensal bacteria before and after 
the treatment was 1.7 × 107 CFU/ml and 1.2 × 107 CFU/
ml, respectively, and the p was 0.616 (p > 0.05) (Fig. 3A), 
indicating lack of significant change in bacterial con-
tent after α-viniferin treatment. On the other hand, 
the average number of S. aureus before and after the 
treatment was 3.8 × 105 CFU/ml and 8.3 × 103 CFU/ml, 
respectively, and the p was 0.002 (p < 0.01) (Fig. 3B). The 
MRSA number was 7.8 × 104 CFU/ml and 2.9 × 103 CFU/
ml, respectively, and the p was 0.008 (Fig. 3C), indicat-
ing a significant reduction in the number of S. aureus 
and MRSA during the clinical trial. Overall, the culture-
based quantification results demonstrate α-viniferin as 
an antibacterial agent with specific activity against the 
staphylococcus group, including MRSA without affect-
ing the nares’ resident normal microbiota. 
qRT-PCR-based quantification. We did qRT-PCR 
using S. aureus- and MRSA-specific primers to evalu-
ate and quantify these organisms in the nares samples. 
We then analyzed the resulting Ct value and found that 
the Ct values for S. aureus and MRSA increased, which 
indicated the reduction of the organism populations. It 
is also noteworthy that there was no noticeable change 
in the Ct value of normal microbiota (p > 0.05) (Fig. 4 ). 
In Fig. 4B, the difference of the Ct value between the 
columns is four, which indicates that the S. aureus 
number was reduced 16-fold while the MRSA number 
decreased 32-fold (Fig. 4C). Since we know that in each 
amplification cycle, the target doubles exponentially, 
and the Ct value is inversely related to the content of 
starting material. To calculate the reduction of bacte-
rial numbers in the samples, we generated a qRT-PCR 
standard curve (Fig. 4D). Comparing the analyzed data 
with this curve, the initial and final average Ct value of 
S. aureus was 31 and 35 (p < 0.01), which corresponded 
to 1.6 × 104 CFU/ml and 1 × 103 CFU/ml, respectively. 
Furthermore, MRSA’s initial and final average Ct 
value was 32 and 37 (p < 0.001), which corresponded 
to 1 × 104 CFU/ml and 3.2 × 102 CFU/ml, respectively. 
Based on the Ct values in this study, we can conclude 
that α-viniferin treatment did not significantly change 
the microbiota, but the prevalence of S. aureus, includ-
ing MRSA, changed significantly. These findings dem-
onstrated the specific antimicrobial effectiveness of 
α-viniferin against S. aureus and MRSA. 
NGS-based 16s rRNA profiling. To determine 
the whole bacterial composition throughout the 
α-viniferin-treatment period, we did 16S rRNA ampli-
con sequencing. Based on the results, the Staphylococ-
caceae family and Staphylococcus genus were the most 
abundant in the nares, covering 51.04% and 51.03% 
of the whole microbial community. After α-viniferin 
treatment, we observed that the organisms decreased 
from 51.04% to 23.99% at the family level and 51.03% 
to 23.99% at the genus level (Fig. 5).
Fig. 3. Culture-based quantification. Nasal swab samples of 0 and 10th days were collected and incubated in nutrient agar, staphylococcus 
agar media 110, and staphylococcus agar media 110 containing methicillin antibiotic for 48 hours at 37°C by using spread plate technique. 
After this period, antimicrobial activity was determined by the colony forming unit (CFU) method against normal flora (A), S. aureus 
(B), and MRSA (C), respectively. The experiments were performed in triplicate, and the data are represented as mean values and standard 
deviations. *Statistical significance vs. drug-free control using unpaired two-tailed Students’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001).
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Fig. 4. qRT-PCR-based quantification. Nares swab 
samples of 0 and 10th days were collected, follow-
ing by DNA extraction and qRT-PCR was per-
formed. Antimicrobial activity of α-viniferin (A, 
B, C) was determined by comparing the resulting 
Ct value with the standard curve (D) against nor-
mal flora, S. aureus, and MRSA, respectively. The 
experiments were carried out 3 times, and the data 
are given as mean values and standard deviations. 
* Statistical significance vs. drug-free control using 
unpaired two-tailed Students’ t-test (*p < 0.05, 
**p < 0.01, ***p < 0.001).
Fig. 5. NGS-based 16S rRNA profiling. To know the whole bacterial composition throughout the α-viniferin treatment, we conducted 16S 
rRNA amplicon sequencing with 0th (α-viniferin-free) and 10th days (α-viniferin treated) nasal swab samples, and the resulting data was 
analyzed by Ezcloud software. Staphylococcaceae is the most dominant family, which decreased from 51.04% to 23.99% (A), and Staphylo-
coccus is the most abundant among the genus level group that reduced from 51.03% to 23.99% (B) after the α-viniferin treatment.
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Table II
Number of genes (FC cutoff > 2 and 5) regulated in S. aureus by 1× and 2× MIC α-viniferin treatment for 8 hours at 37°C,







1 × MIC 2 × MIC 1 × MIC 2 × MIC
up down downup downup downup
 1 DNA metabolism  92 9 2 20 11 2 0 2 0
 2 Energy metabolism 126 10 17 22 31 1 5 5 11
 3 Protein synthesis 85 5 4a 12 15 0 0 1 1
 4 Transport and binding proteins 195 29b 32b 42a 48b 4 4 16b 19
 5 Protein fate 77 5 4a 13 10 2 1 6 1
 6 Amino acid biosynthesis 62 13b 5 25 5a 3a 2 11 2
 7 Signal transduction 13 0 3 0 3 0 0 0 2
 8 Purines, pyrimidines, nucleosides, and nucleotides 37 1 5 2 7 1 0 1 2
 9 Regulatory functions; Signal transduction 9 0 2 1 4 0 1 0 1
10 Cellular processes 90 9 11 15 21 0 5 5 8
11 Biosynthesis of cofactors, prosthetic groups, 
 and carriers; Transport and binding proteins 3 0 2 0 2 0 1 0 1
12 Central intermediary metabolism 21 1 4 6 7 0 2 1 3
13 Regulatory functions 55 3 8 6 11 1 1 1 3
14 DNA metabolism; Regulatory functions; 
 Cellular processes 1 0 0 0 0 0 0 0 0
15 Cell envelope 50 4 4 8 11 0 0 1 1
16 Cellular processes; Transport and binding proteins 13 5b 2 5 1 2a 0 3a 0
17 Energy metabolism; Purines, pyrimidines, nucleosides, 
  and nucleotides 2 0 0 0 1 0 0 0 0
18 Transcription 22 1 2 3 3 0 0 0 1
19 Biosynthesis of cofactors, prosthetic groups, and carriers 99 8 7a 25a 13a 1 3 6 2
20 Protein fate; Energy metabolism 4 0 1 1 1 0 0 0 1
21 Fatty acid and phospholipid metabolism 24 0 2 3 3 0 0 0 0
22 Transport and binding proteins; Signal transduction 10 0 2 2 3 0 0 0 1
23 Hypothetical proteins 26 3 3 5 4 1 1 3 3
24 Cell envelope; Central intermediary metabolism 1 0 0 0 0 0 0 0 0
25 DNA metabolism; Mobile and extrachromosomal 
 element functions 3 1 0 1 0 0 0 1 0
26 Cellular processes; DNA metabolism 8 0 2 1 4a 0 0 0 0
27 Protein fate; Transport and binding proteins 1 0 0 0 0 0 0 0 0
28 Regulatory functions; Purines, pyrimidines,  
 nucleosides, and nucleotides 1 0 0 0 0 0 0 0 0
29 Protein fate; Cellular processes 6 1 0 1 0 0 0 0 0
30 Energy metabolism; Central intermediary metabolism 1 0 0 0 0 0 0 0 0
31 Regulatory functions; Cellular processes 2 0 1 0 1 0 0 0 0
32 Signal transduction; Regulatory functions 1 0 0 0 0 0 0 0 0
33 DNA metabolism; Cellular processes 3 0 1 1 1 0 0 0 0
34 Biosynthesis of cofactors, prosthetic groups, 
 and carriers; Central intermediary metabolism 1 0 0 1 0 0 0 0 0
35 Mobile and extrachromosomal element functions 32 1 1 5 1 0 0 0 0
36 Protein synthesis; Cellular processes; 
 Regulatory functions 1 0 0 0 0 0 0 0 0
37 Cellular processes; Cell envelope 2 0 0 0 0 0 0 0 0
38 Transport and binding proteins; Cellular processes 2 0 0 0 0 0 0 0 0
39 Protein fate; Cell envelope 3 0 1 1 0 0 0 0 0
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a – p < 0.05; b – p < 0.01; c – p < 0.001
40 Cell envelope; Cellular processes 4 0 0 1 1 0 0 0 0
41 Cell envelope; Transport and binding proteins 4 1 0 1 0 0 0 0 0
42 Regulatory functions; Transport and binding proteins 2 0 0 0 1 0 0 0 0
43 DNA metabolism; Regulatory functions 3 0 0 0 0 0 0 0 0
44 Cellular processes; Protein fate 4 0 0 0 1 0 0 0 0
45 Mobile and extrachromosomal element functions; 
 Regulatory functions 3 0 1 0 1 0 0 0 1
46 Mobile and extrachromosomal element functions; 
 Hypothetical proteins 2 0 0 0 0 0 0 0 0
47 Protein fate; Signal transduction 3 0 1 1 1 0 0 0 0
48 Regulatory functions; Amino acid biosynthesis 2 0 1 0 0 0 0 0 0
49 Purines, pyrimidines, nucleosides, and nucleotides; 
 Central intermediary metabolism 1 0 0 0 0 0 0 0 0
50 Protein synthesis; Biosynthesis of cofactors, 
 prosthetic groups, and carriers 1 0 0 0 0 0 0 0 0
51 Regulatory functions; Central intermediary metabolism 2 0 1 0 1 0 0 0 0
52 Protein fate; Regulatory functions 3 0 0 2 0 0 0 0 0
53 Regulatory functions; Energy metabolism 1 0 1 0 0 0 0 0 0
54 Mobile and extrachromosomal element functions; 
 Protein fate 1 0 0 1 0 0 0 0 0
55 Regulatory functions; Central intermediary 
 metabolism;  Signal transduction 1 0 1 0 1 0 1 0 1
56 Central intermediary metabolism; Cell envelope 1 0 0 0 0 0 0 0 0
57 Cellular processes; Mobile and extrachromosomal 
 element functions 4 0 0 0 0 0 0 0 0
58 Protein fate; Purines, pyrimidines, nucleosides, 








1 × MIC 2 × MIC 1 × MIC 2 × MIC
up down downup downup downup
Exploring α-viniferin-induced gene expression in 
S. aureus. We verified the integrity of extracted total 
RNA by the sharpness of the ribosomal RNA bands 
visualized on the 2% agarose gel using ethidium bro-
mide. We observed distinct 23S and 16S rRNA bands 
without degradation in all samples tested (Fig. S1). 
Then, we did transcriptional profiling of S. aureus using 
2,842 whole-genome RNA sequencing to measure the 
effects of α-viniferin relative to a sample of logarithmi-
cally growing S. aureus. Compared with the drug-free 
control group, 583 (1 × MIC, 8 h) and 1,057 (2 × MIC, 
8 h) genes had expression levels altered 2-fold. When 
the FC cutoff was raised to 5-fold, we found that 94 
(1 × MIC, 8 h) and 256 (2 × MIC, 8 h) genes had altered 
expression levels in the α-viniferin-treated group 
(Table II). To better understand the transcriptional 
response of S. aureus to α-viniferin, we adopted more 
specific functional classifications. We used a hypergeo-
metric distribution to determine whether the enrich-
ment of genes within a particular functional category in 
response to α-viniferin-treatment was significant. We 
observed that protein synthesis, transport, and binding 
proteins, protein fate, amino acid biosynthesis, cellular 
processes; transport and binding proteins, biosynthesis 
of cofactors, prosthetic group, and carriers, cellular pro-
cesses, and DNA metabolism functional groups were 
significantly reduced five-fold when the bacteria were 
treated with a drug at a concentration equal to 2 × MIC 
(Table III). These results demonstrated how α-viniferin 
inhibited the growth of the Staphylococcus group.
Discussion
In a 10-day clinical trial, we investigated the decolo-
nization efficiency of α-viniferin as an S. aureus-specific 
drug candidate. Before the clinical trial, we checked 
the specific toxicity of α-viniferin and two other ref-
erence drugs against 20 bacterial isolates. α-Viniferin 
showed excellent antibacterial effectiveness against the 
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Table III
Number of (FC cutoff > 2 and 5) specific regulated gene groups in S. aureus by 1 × and 2 × MIC α-viniferin treatment for 8 hours at 37°C, 
according to functional classification.
 3 Protein synthesis
 a tRNA aminoacylation 12 1 1 1 4 0 0 1 1
 b Ribosomal proteins: synthesis and modification 25 2 3 5 4 0 0 0 0
 c tRNA and rRNA base modification 37 2 0 6 4 0 0 0 0
 d Other 85 9 8 16 18 2 0 6 2
 e Translation factors 7 0 0 0 2 0 0 0 0
 4 Transport and binding proteins
 a Amino acids, peptides and, amines 32 5 2 7 4 0 1 4a 1
 b Cations and iron carrying compounds 72 8 9 12 10 1 0 2 3
 c Carbohydrates, organic alcohols, and acids 27 4 6 7 8 1 1 3 5b
 d Anions 18 4 2 5 10 0 1 2 5
 e Anions; Other 1 1 0 1 0 0 0 1a 0
 f Other 85 9 8 16 18 2 0 6 2
 g Nucleosides, purines and, pyrimidines 6 0 3 0 5b 0 1 0 3b
 h Unknown substrate 20 3 6 6 6 0 0 1 2
 i Cations and iron carrying compounds; Anions 3 0 1 0 2 0 0 0 0
 5 Protein fate
 a Protein and peptide secretion and trafficking 27 2 2 3 5 0 0 2 0
 b Degradation of proteins, peptides, and glycopeptides 18 1 0 5 0 0 0 2 0
 c Protein modification and repair 20 0 0 0 3 0 0 0 0
 d Protein folding and stabilization 4 2a 1 2 1 2b 1 2a 1
 e Degradation of proteins, peptides, and glycopeptides;
  Protein folding and stabilization 6 0 0 3 0 0 0 0 0
 f Degradation of proteins, peptides, and glycopeptides;
  Protein modification and repair 1 0 0 0 0 0 0 0 0
 g Protein and peptide secretion and trafficking;
  Protein modification and repair 1 0 1 0 1 0 0 0 0
 6 Amino acid biosynthesis
 a Aspartate family 15 3 1 8b 0 1 0 3a 0
 b Serine family 11 3 0 4 2 0 0 1 0
 c Glutamate family 7 0 3a 0 2 0 1 0 1
 d Pyruvate family 12 5b 1 8 1 0 1 5 1
 e Histidine family 8 0 0 2 0 0 0 0 0
 f Aromatic amino acid family 9 2 0 3 0 2b 0 2 0
16 Cellular processes; Transport and binding proteins
 a Toxin production and resistance; Other 13 3 1 4 1 2a 0 3a 0
 b Toxin production and resistance; Unknown substrate 3 2a 1 1 0 0 0 0 0
 c Detoxification; Other 1 0 0 0 0 0 0 0 0
19 Biosynthesis of cofactors, prosthetic groups, and carriers
 a Glutathione and analogs 4 0 0 1 1 0 0 0 0
 b Menaquinone and ubiquinone 17 0 0 3 1 0 0 0 0
 c Other 85 9 8 16 18 2 0 6 2
 d Heme, porphyrin, and cobalamin 19 3 2 7a 2 0 1 2 1
 e Folic acid 6 0 0 0 0 0 0 0 0







1 × MIC 2 × MIC 1 × MIC 2 × MIC
up down downup downup downup
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Staphylococcus group. On the other hand, several 
reports showed VAN resulted in rapid depletion of 
intestinal microflora and significantly promoted the 
growth of vancomycin-resistant bacteria (Edlund et al. 
1997; Isaac et al. 2016) highlighting the drawbacks of 
VAN even though it was the most effective anti-Sta-
phylococcus reference drug in the present MIC study. 
We have also tested MET as another reference drug.
In this study, we analyzed the nasal swab sam-
ples through culture-based techniques to investigate 
the antimicrobial effectiveness of α-viniferin against 
the nares normal microflora, S. aureus, and MRSA. 
α-Viniferin was active against S. aureus and MRSA but 
showed no activity against nasal microflora. To further 
confirm this, we did qRT-PCR using S. aureus- and 
MRSA-specific primers since precise detection and 
quantification are achievable by using this technique. 
Expectedly, α-viniferin was active against S. aureus and 
MRSA while preserving the resident nasal microflora. 
Moreover, α-viniferin improved the skin moisture con-
tent, which is essential in maintaining skin plasticity 
and barrier integrity without toxicity.
In addition, we used NGS-based 16S rRNA pro-
filing to investigate further the clinical efficiency of 
α-viniferin against the Staphylococcus group. We also 
evaluated the effect of α-viniferin against normal nasal 
microflora using NGS, where NGS upgrades DNA 
sequencing methodology to the next level through 
parallel sequencing processes that enable the simulta-
neous sequencing of different DNA fragments while 
providing precise identification results (Abayasekara 
et al. 2017). The NGS results demonstrated Staphylococ-
cus as the most dominant group in the anterior nares, 
supporting similar published findings (Hogan et al. 
2016; Warnke et al. 2016; Lu et al. 2018). α-Viniferin 
drastically reduced the number of Staphylococcus in 
the anterior nares, while the decrease in the number 
of other bacteria groups was statistically insignificant. 
The important thing is that α-viniferin significantly 
decreased the Staphylococcus group. This molecular 
approach provides evidence of the antimicrobial spec-
ificity of α-viniferin as a pathogen-specific potential 
drug, and the results were consistent with the culture 
and qRT-PCR-based findings. The results were also in 
agreement with a previous study finding that demon-
strated the in vitro activity of α-viniferin against MRSA 
(Seo et al. 2017). 
RNA sequencing technology is a powerful tool 
for studying the molecular basis of genetic interac-
tions; it makes it possible to examine the relatively 
unbiased measurements of expression levels across 
the entire length of a transcript using high-through-
put sequencing platforms (Pickrell et al. 2010). In the 
present study we did RNA sequencing to understand 
α-viniferin-induced gene expression in S. aureus. Our 
results showed that α-viniferin inhibits the growth 
of S. aureus, which may be attributed to its effects on 
some of the gene groups mentioned. Further research 
is required to elucidate this finding. In conclusion, we 
demonstrated the clinical efficiency of α-viniferin as 
a potential S. aureus-specific drug candidate for the first 
time through a clinical trial.
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